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Chronic hepatitis C viremia (HepC) has been associated with numerous renal manifestations both in native kidneys and in
the setting of renal transplantation. Glomerulonephritis (GN) of the renal allograft in the setting of HepC most commonly
manifests as type 1 membranoproliferative GN (MPGN), either representing recurrence of the original disease or arising de novo.
Other GNs were reported after transplantation in the patient with HepC including membranous nephropathy and thrombotic
microangiopathy, as well as an enhanced susceptibility to transplant glomerulopathy. We describe the first case of de novo fibrillary
GN in a renal transplant patient with HepC where the primary renal disease was biopsy proven type 1 MPGN. We discuss this
relationship in detail.
1. Introduction
Chronic hepatitis C (HepC) affects 170 million persons
worldwide and is a leading cause of cirrhosis and hepatocel-
lular carcinoma. Renal disease is a prominent extrahepatic
complication of HepC, typically manifesting as membra-
noproliferative glomerulonephritis (MPGN) in the setting
of cryoglobulinemia (cryo) [1]. In addition, HepC remains
a major concern after renal transplantation, affecting both
patient and graft survival [2]. A strong association is doc-
umented with development of posttransplant diabetes mel-
litus, de novo glomerulonephritis, and possibly transplant
glomerulopathy. Here we report a patient with HepC and
biopsy proven MPGN, who progressed to end-stage, and
after 2 years on dialysis received a deceased donor renal
transplant. Eight years later, in the setting of proteinuria and
declining renal function, transplant biopsy revealed de novo
FGN.
2. Case Report
A 56-year-old Caucasian male with HepC presented in 1994
with an elevated serum creatinine and nephrotic-range pro-
teinuria. He had a history of hypertension, nephrolithiasis,
and diverticulitss. Renal biopsy revealed type 1 MPGN.
Symptomatic cryoglobulinemic vasculitis (cryoV) developed,
which was treated in 1995 with plasmapheresis, intravenous
cyclophosphamide, and steroids. Renal function progres-
sively deteriorated necessitating dialysis in 1996. Treatment
with interferon was curtailed, owing to severe psychiatric
symptoms, and the patient remained viremic and on dialysis.
A deceased donor renal transplant was performed in April
2003. An early Banff 1A rejection was treated with a course of
IV methylprednisolone with resolution. Immunosuppressive
therapy included cyclosporine and sirolimus. A biopsy in
June 2003 showed no signs of rejection. In July 2003 cryoV
reappeared with asthenia, severe arthralgias, purpura, and
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Figure 1: Photomicrograph of the kidney biopsy showing 3
glomeruli with prominent and advanced accumulation of amor-
phous, eosinophilic material (H & E, 40x).
abdominal pain. The patient was viremic and hypocomple-
mentemic with a cryocrit from 2 to 5%. Treatment included
plasmapheresis and a 4-week course of rituximab, which
produced symptomatic improvement. The serum creatinine
ranged from 1.8 to 2.5mg/dL from 2003 until 2010, when
it increased to 4.5mg/dL. A biopsy in June 2010 showed
moderate acute tubular damage andmild chronic calcineurin
inhibitor toxicity. Electron microscopy revealed a mild
glomerulopathy consistentwith calcineurin inhibitor toxicity.
No evidence of recurrent MPGN was present. Dialysis was
required for several weeks, but renal function spontaneously
improved, and creatinine stabilized around 2.5mg/dL. Over
the course of the next year, creatinine slowly increased and
proteinuria became nephrotic range. The protein/creatinine
ratio was 4991mg/g; SPEP showed decreased albumin and
UPEP a pattern consistent with glomerular proteinuria.
Both serum and urine immunofixation were negative. ANA
was negative. HCV RNA PCR revealed 17,369,084 IU/mL.
Serum cryo was negative, although they had been inter-
mittently positive at 1-2%. C3 was normal and C4 was
undetectable. A biopsy in December 2011 showed prominent
and advanced accumulation of amorphous, eosinophilic
material in glomeruli, interstitial fibrosis, tubular atrophy,
and vascular intimal sclerosis (Figure 1). Electronmicroscopy
showed 10–15 nm fibrils in the mesangium and glomerular
capillary walls (Figure 2). A Congo red stain was negative.
Renal function progressively deteriorated and dialysis was
initiated in March 2012.
Our patient is the first reported case of FGN in a
renal transplant developing in the setting of HepC. The
morphologic features of the final transplant biopsy are clearly
different from those of the native kidney (type I MPGN) and,
thus, indicate a de novo process.
Figure 2: Electron micrograph showing an accumulation of ran-
domly oriented, 18 nm in diameter fibrils in the subendothelial space
between the lamina densa (upper right) and the endothelial cell
(bottom left). Magnification: 20,000x.
3. Discussion
HepC has been associated with various renal manifestations
in both native and transplant kidneys. HepC is the cause of
the large majority of cases of essential mixed cryo (EMC),
whether due to type II (monoclonal IgM against polyclonal
IgG) or type III (polyclonal IgM against polyclonal IgG)
cryo [3]. This B-cell proliferative disorder is frequently
complicated by glomerulonephritis (GN). About 75% of cases
of GN complicating EMC are found with type II cryo and
about 25% with type III [4]. Histologically, the lesions are a
type 1 MPGN. Features that suggest an EMC etiology include
prominent monocytic inflammation, large hyaline thrombi,
and organization of deposits by electron microscopy (EM).
Our patient’s initial clinical presentation and native kidney
biopsy clearly fit this description of cryo GN.
In a seminal report Johnson et al. found MPGN in all 8
HepC positive patients referred for evaluation of proteinuria
[5]. Only 5 of the 8 had detectable cryo, although all 8 had
low serum complement and positive RF. Organized deposits
consistent with cryo were found in 3 of 4 examined speci-
mens. In a follow-up study involving 34 HepC patients with
proteinuria, 31 had MPGN and 3 had an acute proliferative
and exudative GN [6]. Only 20 of 34 had cryo detectable on
presentation.Over time, however, 9more becamepositive (29
of 34 total). Twenty of the 29 positive patients had symptoms
of EMC.Others have confirmed the association of HepCwith
MPGN [7, 8]. Most but not all of the reported cases had
detectable cryo. In a series of 105 biopsies of native kidneys,
Cosio at al. did not find an increased incidence of HepC in
noncryoMPGN and concluded that the relationship between
HepC and MPGN only holds in the presence of EMC [8].
Other glomerulopathies have been associated withHepC.
Membranous nephropathy (MN) is documented in case
reports [9]. Unlike MPGN, cryo and RFs are usually not
found, and serum complement is usually normal. FGN or
immunotactoidGNhas been associated withHepC in several
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case reports [10–12]. In a series of 6 patients (4 with FGN
and 2 with ITGN) reported in 1998, all were negative for
cryo on presentation [13]. One patient, however, did develop
them over time. This is somewhat analogous to our patient
who had intermittent positivity. In a follow-up report in 2003,
of 67 patients (61 with FGN and 6 with ITGN), HepC was
found in 17% [14]. By contrast, however, in another series of
66 patients with FGN, only 3% had HepC [15]. In the report
fromCosio et al. [8], HepCwas significantlymore frequent in
patients with focal segmental glomerulosclerosis (FSGS) than
in controls, but this was only true for intravenous drug users.
In a series of 303 Egyptian patients presentingwithGN,HepC
was found in 38% [16].This contrasts with a rate of 16% in the
general Egyptian population. Of the 50 HepC patients from
this series, 18 had type I MPGN, 9 type II MPGN, 12 FSGS, 2
MN, and 9 mesangioproliferative GN. Cryo were found in 27
of these 50 patients.
In order to establish the causality of HCV in these various
disorders, numerous groups have sought evidence in renal
tissue ofHCVRNAby polymerase chain reaction (RCR) or in
situ hybridization (ISH), as well as detection of viral proteins
by indirect immunofluorescence (IIF) or immunohistochem-
istry (IH). In the Egyptian series noted above, IH for viral
proteins was negative in all patients studied [16]. Electron
microscopy detected particles consistent with HCV in 50%
of cases, and PCR detected RNA in 4 of 21 cryo patients and 5
of 21 noncryo ones. Sansonno et al. studied 12 HepC patients
withMPGN and type II cryo [17]. After electroelution, HCV-
related proteins were detected in 8 of 12 patients by IH; all 8
HCVnegative patients withMPGNhadno positive reactions.
Using laser capturemicrodissection to extract glomeruli from
20 HepC patients with various histologic types, the same
group found HCV detectable RNA in 65% of glomeruli [18].
Positivity ranged from 33% of glomeruli in patients with IgA
nephropathy to 83% of glomeruli in those withMPGN; HCV
core protein was detected in an equal number of glomeruli as
was RNA within each histologic type. Okada et al. detected
HCV core protein by IIF in 2 patients withMN (both negative
for RF and cryo) [19]. Cao et al. used IH to detect the NS3
protein in 21 HCV antibody positive patients with various
types of GN [20]. This antigen was detected in 6 of the 21
(3 MPGN, 1 IgAN, 1 MN, and 1 amyloid); only 4 of the
6 were serum RNA positive. Immunoelectron microscopy
showed that the antigen was localized mainly in electron
dense deposits and in amyloid fibrils. Finally, in a study of 9
HepCMNpatients, viral RNA (both genomic and replicative)
and protein were detected in the perinuclear area of tubular
epithelial cells by ISH and IH andwere associatedwith greater
interstitial inflammation/fibrosis compared to HCV negative
MN patients [21]. It remains unclear if HCV has a causal role
in these various glomerulopathies, with the exception of type
1 MPGN in the setting of EMC.
The incidence of HCV in patients on dialysis varies
between 10 and 50% [22]. The same rate applies to patients
who have received a renal transplant. Numerous studies have
shown reduced patient survival after renal transplantation in
case of HepC. This increased mortality may be due to post-
transplant diabetes (strongly linked to HepC), cardiovascular
disease, liver disease, and/or infection [2, 22]. Graft survival
is also shortened byHepC. It still remains beneficial to receive
a transplant as opposed to remaining on dialysis.
Proteinuria and the development of de novo glomeru-
lopathy have been ascribed to HepC in renal transplantation.
In a 1998 study of 322 consecutive transplants, Hestin et
al. showed by multivariable analysis that HepC conferred
a significant relative risk of 5.36 on the development of
persistent proteinuria (>1 g/day for 3 months) [23]. Roth
et al. studied 8 patients with proteinuria exceeding 1 g/day
from a cohort of 98 HepC renal transplants [24]. Three had
what was previously termed as chronic allograft nephropathy
(CAN), but the other 5 had de novo development of type
1 MPGN. All 5 had undetectable cryo, but 2 did have low
complement levels and positive RFs, and 2 patients also had
organized deposits on EM. Cruzado et al. found 9 patients
with >1.5 g/day proteinuria from a series of 94 HepC renal
transplants [25]. One patient had MN, 2 CAN, and the
remaining 6 de novo type 1 MPGN. All 6 did have detectable
cryo, but nonewere symptomatic. IgM-RFswere detectable in
the cryoglobulins, but 5 of the 6 had negative serumRF. HCV
RNAwas concentrated in the cryoglobulins, with enrichment
of up to 18,000%. The same group evaluated 96 transplant
biopsies performed at least 3 months after transplantation
that did not show acute rejection [26]. Forty-four of the 96
(46%) were fromHepC patients, and 63% of these showed de
novo glomerulopathy (20 MPGN and 8 MN). This compares
to 14% in those negative forHCV (3MPGN, 4MN). Similarly,
O¨zdemir et al. studied 165 renal transplants of whom 44
were HCV antibody positive [27]. Of the 24 RNA+ patients,
15 developed de novo glomerulopathy (11 MPGN, 4 MN);
only 8 of the 121 HCV negative patients did so. No case had
detectable cryo. However, in a series of 2000 renal transplants
(400 HepC), 15 cases of MN were detected, 10 of which were
clearly de novo; no MPGN was apparently detected in this
large series [28].
Other glomerular manifestations of HCV have been
reported in renal transplants. Cosio et al. noted HCV in 29%
of 41 patients with acute transplant glomerulitis and 33%of 27
patients with transplant glomerulopathy (TG) compared to
1.8% of 105 transplant patients with neither one [8]. Baid et al.
studied 18 HepC transplants out of 339 total transplants [29].
Five of these 18 developed a thrombotic microangiopathy
(TMA) a mean of 14 days after transplantation. All 5 had
detectable anticardiolipin antibodies, as opposed to 1 of the
13 without TMA and 0 of 7 TMA patients without HCV.
In a series of 209 indication biopsies for chronic renal
allograft dysfunction from the same institution, 25 cases
of TG were detected [30]. HepC was detected in 36% of
these compared to 7% in a control group with calcineurin
inhibitor nephrotoxicity and 3.6% in their overall transplant
population. A TMAwas detectable in 32% of the TG patients
as well, and there was significant overlap between HCV and
TMA in the setting of TG.
Glomerular organized deposits detected by EM as in our
patient may be nonspecific findings or may be diagnostic of
various conditions [31, 32]. Amyloid fibrils of any etiology
are randomly oriented, nonbranching, and usually measure
about 10 nm in diameter. Congo red positivity with green
birefringence under polarized light is diagnostic, as is staining
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with thioflavin T. Cryoglobuins are frequently organized, as
noted above, and may take various shapes depending on the
type involved; interestingly, EM examination of cryoglobu-
lins obtained from serum may mimic the morphology of
those deposited in tissues [33]. The immune complexes of
systemic lupus may occasionally be organized, appearing to
resemble fingerprints [32].
The lesion termed as FGN, found in about 1% of renal
biopsies, is characterized by the EM findings of randomly
oriented, nonbranching fibrils about twice the diameter of
amyloid (about 20 nm) [14, 15, 31, 32]. They are usually found
in the glomerular basement membrane or paramesangial
area. Tubular deposits are distinctly unusual, and except
for isolated case reports they are not found outside the
kidney. They are Congo red and thioflavin T negative but
regularly stain for immunoglobulins, usually IgG (especially
subclass IgG4), and complement by immunofluorescence
(IF). Various light microscopic features may be obtained,
including MPGN, mesangial proliferative GN, MN, and dif-
fuse sclerosis. Patients present with hematuria, proteinuria,
and renal impairment, and about half progress to ESRD in
2–4 years. It may recur following renal transplantation in
about 50% of cases, but it tends to progress at a much slower
rate in the transplant [34]. The largest series reported to date
found an underlying paraproteinemia (PP) in 15–17% of such
cases [15]. Some authors feel that detection of a PP excludes
a diagnosis of idiopathic FGN, suggesting that the fibrils are
a manifestation of the underlying plasma or B-cell disorder
[35]. This remains an area on contention.
Related to FGN, but occurring about one-tenth as fre-
quently, is ITG. This has a similar clinical presentation,
light microscopic findings, and IF (except more commonly
monoclonal) but differs by EM. Here, the fibrils are larger
(usually, but not always, >30 nm), hollow (when viewed
under 30,000x power or less), and/or organized (at least
focally) into bundles. Patients with such deposits are more
likely than those with the fibrils of FGN to have an underlying
PP and/or B-cell neoplasm, occurring in over 50% of cases.
This has led to the argument that FGN and ITG should be
viewed as discreet entities. Others feel, however, that after
excluding PPs, there would be no difference between them
other than the diameter of the fibrils [34]. Neither FGN nor
ITG frequently occurs de novo in renal allografts. Besides our
case, we know of one case of de novo ITG associated with
CMV infection [36] and another in a patient with systemic
lupus [37]. One case of FGN from a large series was presumed
to bede novo, although therewas nonative kidney biopsy [14].
As noted above, hepatitis C has been associated with FGN
and is clearly associated with cryo. Since cryoglobulins are
frequently organized, the fibrils detected in our patient, and
other cases with HCV, may simply be cryoglobulin deposits.
Indeed, it has been hypothesized that FGN may represent a
forme fruste of cryo [13, 34]. Although our patient’s initial
biopsy had the more characteristic lesion of type 1 MPGN,
the final transplant biopsy clearly did not. It is possible that
after transplantation, due to immunosuppressivemedications
and/or effects of the allograft itself, the antigen/antibody
ratio or other features of the immune complexes have been
altered such that fibril formation was fostered. Perhaps in
some patients with HepC this may occur from the outset,
resulting in typical FGN in the native kidney. Finally, HCV-
related EMC is definitively a B-cell proliferative disorder
[38]. Considering the known association of such neoplastic
disorders and PP with FGN and/or ITG [39], it may be
that through the development of a neoplasm that HepC is
linked to fibrillogenesis, independent of its ability to induce
cryoglobulin formation.
In conclusion, we present the first documented case
of FGN developing de novo in a renal transplant patient
chronically infected with HCV.
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